The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Rivastigmine for Dementia Associated with Parkinson's Disease
Open accessAbstract
BACKGROUND: Cholinergic deficits are prominent in patients who have dementia associated with Parkinson's disease. We investigated the effects of the dual cholinesterase inhibitor rivastigmine in such patients. METHODS: Patients in whom mild-to-moderate dementia developed at least 2 years after they received a clinical diagnosis of Parkinson's disease were randomly assigned to receive placebo or 3 to 12 mg of rivastigmine per day for 24 weeks. Primary efficacy variables were the scores for the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog) and Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change (ADCS-CGIC). Secondary clinical outcomes were the scores for the Alzheimer's Disease Cooperative Study-Activities of Daily Living, the 10-item Neuropsychiatric Inventory, the Mini-Mental State Examination, Cognitive Drug Research power of attention tests, the Verbal Fluency test, and the Ten Point Clock-Drawing test. RESULTS: A total of 541 patients were enrolled, and 410 completed the study. The outcomes were better among patients treated with rivastigmine than among those who received placebo; however, the differences between these two groups were moderate and similar to those reported in trials of rivastigmine for Alzheimer's disease. Rivastigmine-treated patients had a mean improvement of 2.1 points in the score for the 70-point ADAS-cog, from a baseline score of 23.8, as compared with a 0.7-point worsening in the placebo group, from a baseline score of 24.3 (P<0.001). Clinically meaningful improvements in the scores for the ADCS-CGIC were observed in 19.8 percent of patients in the rivastigmine group and 14.5 percent of those in the placebo group, and clinically meaningful worsening was observed in 13.0 percent and 23.1 percent, respectively (mean score at 24 weeks, 3.8 and 4.3, respectively; P=0.007). Significantly better outcomes were seen with rivastigmine with respect to all secondary efficacy variables. The most frequent adverse events were nausea (affecting 29.0 percent of patients in the rivastigmine group and 11.2 percent of those in the placebo group, P<0.001), vomiting (16.6 and 1.7 percent, P<0.001), and tremor (10.2 and 3.9 percent, P=0.01). CONCLUSIONS: In this placebo-controlled study, rivastigmine was associated with moderate improvements in dementia associated with Parkinson's disease but also with higher rates of nausea, vomiting, and tremor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a double-blind clinical trial in which individuals were randomly assigned to receive rivastigmine (362 individuals) or the placebo (172 individuals), participants treated with rivastigmine had increased scores (mean improvement of 2.1 points) on the 70-point Alzheimer’s Disease Assessment Scale, whereas those in the placebo group had decreased scores (decrease of 0.7 points) (P < 0.001).446”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [446]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Self-citationDelis-Kaplan Executive Function System
Delis, D. C., Kaplan, E., & Kramer, J. H. (2012) · PsycTESTS Dataset · doi:10.1037/t15082-000 · Cited by 2,683
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Cited by
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationDiagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004058 · Cited by 4,476
Self-citationClinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationDiagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Lees, A. J., Hardy, J., & Revesz, T. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60492-x · Cited by 1,956
Self-citationParkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Self-citationSeppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Self-citationClinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,124
Dubois, B., Burn, D., Goetz, C., Aarsland, D., Brown, R. G., Broe, G. A., Dickson, D., Duyckaerts, C., Cummings, J., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21844 · Cited by 1,082
Self-citationCognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
Self-citationThe distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., et al. (2009) · Brain · doi:10.1093/brain/awp245 · Cited by 965
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Dementia and Cognitive Impairment
Hugo, J., & Ganguli, M. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.04.001 · Cited by 902
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 881
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859
“Uncertainty remains about the potential efficacy of trophic factors in PD.(53) None of these studies delivered the trophic factor in an optimal way, and it is”
InfluentialSelf-citationA review of Parkinson's disease
Davie, C. A. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn013 · Cited by 855
Meirow, D., Levron, J., Eldar-Geva, T., Hardan, I., Fridman, E., Zalel, Y., Schiff, E., & Dor, J. (2005) · New England Journal of Medicine · doi:10.1056/nejmc055237 · Cited by 851
Yogev, G., Giladi, N., Peretz, C., Springer, S., Simon, E. S., & Hausdorff, J. M. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04298.x · Cited by 822
Non‐motor symptoms in Parkinson’s disease
Poewe, W. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02056.x · Cited by 782
Self-citationRaina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis
Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K., Kulisevsky, J., Burn, D., Barone, P., Pagonabarraga, J., Allcock, L., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39d0e · Cited by 748
Self-citationOrganic Carbamates in Drug Design and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501371s · Cited by 739
Dementia associated with Parkinson's disease
Emre, M. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00351-x · Cited by 685
Self-citationWaldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Self-citationThe clinical diagnostic utility of transcranial magnetic stimulation: Report of an IFCN committee
Chen, R., Cros, D., Curra, A., Di Lazzaro, V., Lefaucheur, J.-P., Magistris, M. R., Mills, K., Rösler, K. M., Triggs, W. J., Ugawa, Y., et al. (2008) · Clinical Neurophysiology · doi:10.1016/j.clinph.2007.10.014 · Cited by 612
Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia
Janvin, C. C., Larsen, J. P., Aarsland, D., & Hugdahl, K. (2006) · Movement Disorders · doi:10.1002/mds.20974 · Cited by 593
Self-citationWalker, Z., Possin, K. L., Boeve, B. F., & Aarsland, D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00462-6 · Cited by 592
Self-citationCognitive Impairment in Parkinson’s Disease: The Dual Syndrome Hypothesis
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2013) · Neurodegenerative Diseases · doi:10.1159/000341998 · Cited by 573
Neuropsychiatric symptoms in Parkinson's disease
Aarsland, D., Marsh, L., & Schrag, A. (2009) · Movement Disorders · doi:10.1002/mds.22589 · Cited by 557
Self-citationDLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers
Lippa, C. F., Duda, J. E., Grossman, M., Hurtig, H. I., Aarsland, D., Boeve, B. F., Brooks, D. J., Dickson, D. W., Dubois, B., Emre, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000256715.13907.d3 · Cited by 548
Self-citationAarsland, D., Bronnick, K., Ehrt, U., De Deyn, P. P., Tekin, S., Emre, M., & Cummings, J. L. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.083113 · Cited by 521
Self-citationCognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Svenningsson, P., Westman, E., Ballard, C., & Aarsland, D. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70152-7 · Cited by 499
Self-citationMiyasaki, J. M., Shannon, K., Voon, V., Ravina, B., Kleiner-Fisman, G., Anderson, K., Shulman, L. M., Gronseth, G., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215428.46057.3d · Cited by 487
Aarsland, D., Ballard, C., Walker, Z., Bostrom, F., Alves, G., Kossakowski, K., Leroi, I., Pozo-Rodriguez, F., Minthon, L., & Londos, E. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70146-2 · Cited by 459
Self-citationPriorities in Parkinson's disease research
Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, A., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 436
Emre, M., Tsolaki, M., Bonuccelli, U., Destée, A., Tolosa, E., Kutzelnigg, A., Ceballos-Baumann, A., Zdravkovic, S., Bladström, A., & Jones, R. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70194-0 · Cited by 436
Self-citationParkinson’s disease dementia: a neural networks perspective
Gratwicke, J., Jahanshahi, M., & Foltynie, T. (2015) · Brain · doi:10.1093/brain/awv104 · Cited by 435
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
Long, J. Z., & Cravatt, B. F. (2011) · Chemical Reviews · doi:10.1021/cr200075y · Cited by 425
Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Parkinson's disease: The quintessential neuropsychiatric disorder
Weintraub, D., & Burn, D. J. (2011) · Movement Disorders · doi:10.1002/mds.23664 · Cited by 423
Rolinski, M., Fox, C., Maidment, I., & McShane, R. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006504.pub2 · Cited by 418
Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways
Hilker, R., Thomas, A. V., Klein, J. C., Weisenbach, S., Kalbe, E., Burghaus, L., Jacobs, A. H., Herholz, K., & Heiss, W. D. (2005) · Neurology · doi:10.1212/01.wnl.0000191154.78131.f6 · Cited by 384
Metabolic brain networks associated with cognitive function in Parkinson's disease
Huang, C., Mattis, P., Tang, C., Perrine, K., Carbon, M., & Eidelberg, D. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2006.09.003 · Cited by 361
O’Brien, J. T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 354
Qaseem, A., Snow, V., Cross, J. T., Forciea, M. A., Hopkins, R., Shekelle, P., Adelman, A., Mehr, D., Schellhase, K., Campos-Outcalt, D., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00008 · Cited by 354
Ferreira, J. J., Katzenschlager, R., Bloem, B. R., Bonuccelli, U., Burn, D., Deuschl, G., Dietrichs, E., Fabbrini, G., Friedman, A., Kanovsky, P., et al. (2013) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03866.x · Cited by 348
Self-citationCurrent approaches to the treatment of Parkinson’s disease
Jankovic, J. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2006 · Cited by 342
Calabresi, P., Picconi, B., Parnetti, L., & Di Filippo, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70600-7 · Cited by 338
Deep brain stimulation: Postoperative issues
Deuschl, G., Herzog, J., Kleiner-Fisman, G., Kubu, C., Lozano, A. M., Lyons, K. E., Rodriguez-Oroz, M. C., Tamma, F., Tröster, A. I., Vitek, J. L., et al. (2006) · Movement Disorders · doi:10.1002/mds.20957 · Cited by 313
Self-citationBurn, D., Emre, M., McKeith, I., De Deyn, P. P., Aarsland, D., Hsu, C., & Lane, R. (2006) · Movement Disorders · doi:10.1002/mds.21077 · Cited by 310
Self-citationVisual dysfunction in Parkinson disease without dementia
Uc, E. Y., Rizzo, M., Anderson, S. W., Qian, S., Rodnitzky, R. L., & Dawson, J. D. (2005) · Neurology · doi:10.1212/01.wnl.0000191565.11065.11 · Cited by 308
Gill, S. S., Anderson, G. M., Fischer, H. D., Bell, C. M., Li, P., Normand, S.-L. T., & Rochon, P. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.43 · Cited by 306
Henderson, E. J., Lord, S. R., Brodie, M. A., Gaunt, D. M., Lawrence, A. D., Close, J. C. T., Whone, A. L., & Ben-Shlomo, Y. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00389-0 · Cited by 304
Hall, H., Reyes, S., Landeck, N., Bye, C., Leanza, G., Double, K., Thompson, L., Halliday, G., & Kirik, D. (2014) · Brain · doi:10.1093/brain/awu193 · Cited by 302
Novel pharmacological targets for the treatment of Parkinson's disease
Schapira, A. H. V., Bezard, E., Brotchie, J., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, E., Jenner, P., Novère, N. L., et al. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2087 · Cited by 298
Horstink, M., Tolosa, E., Bonuccelli, U., Deuschl, G., Friedman, A., Kanovsky, P., Larsen, J. P., Lees, A., Oertel, W., Poewe, W., et al. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01547.x · Cited by 297
Self-citationDelivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Anxiety rating scales in Parkinson's disease: Critique and recommendations
Leentjens, A. F. G., Dujardin, K., Marsh, L., Martinez‐Martin, P., Richard, I. H., Starkstein, S. E., Weintraub, D., Sampaio, C., Poewe, W., Rascol, O., et al. (2008) · Movement Disorders · doi:10.1002/mds.22233 · Cited by 275
Self-citationDonepezil for dementia with Lewy bodies: A randomized, placebo‐controlled trial
Mori, E., Ikeda, M., Kosaka, K., & on behalf of the Donepezil‐DLB Study Investigators (2012) · Annals of Neurology · doi:10.1002/ana.23557 · Cited by 274
Wang, H.-F., Yu, J.-T., Tang, S.-W., Jiang, T., Tan, C.-C., Meng, X.-F., Wang, C., Tan, M.-S., & Tan, L. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307659 · Cited by 269
Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis
Stinton, C., McKeith, I., Taylor, J.-P., Lafortune, L., Mioshi, E., Mak, E., Cambridge, V., Mason, J., Thomas, A., & O’Brien, J. T. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14121582 · Cited by 264
Riedel, O., Klotsche, J., Spottke, A., Deuschl, G., Förstl, H., Henn, F., Heuser, I., Oertel, W., Reichmann, H., Riederer, P., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5465-z · Cited by 256
Self-citationSeltzer, B. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.7.1011 · Cited by 256
Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease
Chung, K. A., Lobb, B. M., Nutt, J. G., & Horak, F. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f6128c · Cited by 252
Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective
Robbins, T. W., & Cools, R. (2014) · Movement Disorders · doi:10.1002/mds.25853 · Cited by 235
Cognitive enhancement by drugs in health and disease
Husain, M., & Mehta, M. A. (2011) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2010.11.002 · Cited by 241
Cruise, K. E., Bucks, R. S., Loftus, A. M., Newton, R. U., Pegoraro, R., & Thomas, M. G. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01338.x · Cited by 229
Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study
Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A. J., Schumann, G., Pourcher, E., Gray, J., Thomas, G., Swartz, J., et al. (2012) · Movement Disorders · doi:10.1002/mds.25098 · Cited by 202
Self-citationCurrent treatment options for Alzheimer’s disease and Parkinson’s disease dementia
Y.Y. Szeto, J., & J.G. Lewis, S. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208112754 · Cited by 198
Characteristics of Visual Hallucinations in Parkinson Disease Dementia and Dementia With Lewy Bodies
Mosimann, U. P., Rowan, E. N., Partington, C. E., Collerton, D., Littlewood, E., O'Brien, J. T., Burn, D. J., & McKeith, I. G. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000192480.89813.80 · Cited by 188
Cummings, J., Ritter, A., & Zhong, K. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179901 · Cited by 176
Ballard, C., Sauter, M., Scheltens, P., He, Y., Barkhof, F., van Straaten, E. C. W., van der Flier, W. M., Hsu, C., Wu, S., & Lane, R. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802328142 · Cited by 147
Self-citationWilliams-Gray, C. H., Foltynie, T., Lewis, S. J. G., & Barker, R. A. (2006) · CNS Drugs · doi:10.2165/00023210-200620060-00004 · Cited by 147
Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance
Geula, C., Dunlop, S. R., Ayala, I., Kawles, A. S., Flanagan, M. E., Gefen, T., & Mesulam, M. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15471 · Cited by 102
Parkinson disease psychosis: from phenomenology to neurobiological mechanisms
Pagonabarraga, J., Bejr-Kasem, H., Martinez-Horta, S., & Kulisevsky, J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-023-00918-8 · Cited by 69
Self-citationd’Angremont, E., Begemann, M. J. H., van Laar, T., & Sommer, I. E. C. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.1835 · Cited by 71
Hart, S. J., Visootsak, J., Tamburri, P., Phuong, P., Baumer, N., Hernandez, M., Skotko, B. G., Ochoa‐Lubinoff, C., Liogier D'Ardhuy, X., Kishnani, P. S., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38465 · Cited by 54
Darreh-Shori, T., & Jelic, V. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740330903439717 · Cited by 51
Acetylcholinesterase inhibitors may improve myelin integrity
Bartzokis, G. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.020 · Cited by 41
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Treatment of behavioural symptoms and dementia in Parkinson's disease
Hanagasi, H. A., & Emre, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2005.00317.x · Cited by 24
Self-citationDelirium in the acute phase after stroke: Incidence, risk factors, and outcome
Oldenbeuving, A. W., de Kort, P. L. M., Jansen, B. P. W., Algra, A., Kappelle, L. J., & Roks, G. (2011) · Neurology · doi:10.1212/wnl.0b013e318210411f · Cited by 4
Metadata
- Authors
- Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., Poewe, W., Robillard, A., Rosa, M. M., Wolters, E., Quarg, P., Tekin, S., & Lane, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-12-09
- Volume
- 351
- Issue
- 24
- Pages
- 2509-2518
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2115455636
- Cited by
- 1,223
- References
- 51
- FWCI
- 49.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.